Bio-Modeling Systems: The Mechanisms-Based Mecidicine Company
  • 2019: ANNOUNCEMENT: Lyon October 17-18, 2019: Bio-Modeling Systems invited at the India-France Knowledge Summit 2 to contribute with its CADI Discovery Platform, the other AI, successfully applied to its Indo-French  metabolic disorders therapeutic program UMANG (now Arbuza Regenerate company) addressing  a public health issue concerning 50-100 millions children.
     
  • 2019: PRESS RELEASE: Paris October 1, 2019: Bio-Modeling Systems, the Mechanisms-Based Cosmetics company, is invited to present its CADI™ Discovery platform and 7 outputs at the open Innovation sessions of Cosmetic-360

  • 2019: ANNOUNCEMENT: Lille Juily 2-4, 2019: BMSystems invited as speaker at ANTIMIC 2019: Bacteriophages, Genius and success of precision medicine in infections (ATC HCl) and new tracks for microbiote “surgery” controt with GEMMA microbiota &Autism H2O2O program
      
  • 2019: PRESS-RELEASE: Paris May 30, 2019 : Manuel GEA, CEO BMSystems, rejoint l’Advisory Board Pharma/Santé de Bolero pour renforcer leurs offres et accélérer la convergence recherche clinique et données de vraie vie

  • 2019: ANNOUNCEMENT: Paris May 5, 2019: Bio-Modeling Systems is participating to Neurodegenerative Drug Development Europe Conference in Paris (May 22-23, 2019). Meet us to discover our Alzheimer's and Parkinson’s diseases solutions.
      
  • 2019: ANNOUNCEMENT: BMSystems will be participating to  Polepharma microbiota conference (the N°1 pharmaceutical cluster in Europe) event to present its GEMMA microbiota &Autism H2O2O program !
      
  • 2019: PRESS-RELEASE: Paris April  2, 2019: Bio-Modeling Systems, the 14 M€ H2020 GEMMA (Autism and Microbiota) integrative biology partner, announces the release of the public program web site: www.gemma-project.eu for the World Autism Awareness Day.
     
  • 2019-NEW-YEAR PROGRAM: Paris January 24, 2019: In 2019, our founding motto: “Understand disease mechanisms first. Adapted treatments will follow.” is still highly relevant. FRENCH

  • 2018: POSITION PAPER : Paris December 2, 2018: SMART STRATEGY vs. BIG STRATEGY: How Augmented Intelligence, the other AI, addresses the digital “garbage in garbage out” reality and the life complexity

  • 2018: ANNOUNCEMENT: BMSystems invited to present its CADI Discovery platform and achievements at 4 events in Europe,BioFit,-BioWin-Day,COST EC cluster conference, DGA BtoB  

Bio-Modeling Systems: The Mechanisms-Based Mecidicine Companys

Company

BMSystems' Group Profile

  • Independent Private Company incorporated in 2004, profitable since 2006.
  • 100% owned by its founders (no search for external investors for BMSystems company, open for its spin-offs).
  • The first Mechanisms-Based Medicine company that discovers novel diagnostic, therapeutic & prevention solutions.
  • A clear “Biology” driven company that intensively uses I.T. resources. Inventor and exclusive owner of all its technologies.
  • 24 vFTE* of which 9 vFTE scientists/professionals focused on CADI**™ research.
  • Long term strategic R&D and business collaborations with more than 100 partners’ professionals working on BMSystems’ related R&D programs.
  • Original dual business model that generates revenues through contractual R&D programs & patented novel therapeutic & prevention solutions through collaborative R&D programs with its partners.
  • Company strictly focus on Discovery, the validation phases and the patented discoveries developments are implemented outside the company with selected partners.
  • The largest IT life sciences and healthcare business offer with its strategic IT partner, Persistent Systems (Leading Indian IT company 7000 people, 250 M$, 85% of business in the USA).
  • Member of BiO (USA), MEDICEN (Health, IAR (Industrial biotech) clusters.
  • Member in France of Leem Biotech, Adebiotech, Medef, Centrale-Santé Think Tanks.
  • Founders, member of international organizations (HUGO, CHI, etc…).
  • A responsible Innnovation© company

 BMSystems' Science at a glance

  • Understanding the causal mechanisms of a disease is the first objective. Finding the most adapted biomarkers and solutions are the necessary consequences of the first objective.
  • BMSystems invented CADI™ Discovery in 2004, the first operational "Mechanisms-based Medicine" platform, dedicated to the discovery of cost-effective new diagnostic, therapeutic and prevention solutions for medicine, cosmetics, etc, ...
  • BMSystems' team builds heuristic non-mathematical in-silico models to generate novel disruptive concepts from scientific, medical & health data.
  • CADI™ Discovery and the competition download the document
  • CADI™ Discovery addresses both efficacy and safety issues, the main culprits for the unacceptable R&D attrition rate.
  • BMSystems already generated a significant pipeline of internal Research programs.
  • CADI™ patented novel therapies, already contributed to the creation of two funded Pharma SMEs at clinical stage.:

 BMSystems' dual business model:

  • BMSystems separates its CADI™ research (internal) from the outputs developments (external).
  • BMsystems does not sell its technologies nor give access to them.
  • BMSystems sells the outputs of its research programs to its clients through contractual research programs (options: Access, fees, success fees, Discovery fees).
  • BMSystems shares the outputs of its research programs to its partners through collaborative research programs (each partner finances its costs, shares IP, defines together the development options).
  • The contractual and collaborative businesses are limited to 50% each to secure long run business.
  • BMSystems has repeatedly proven to create business value from its unique new research paradigm.
  • A responsible Innnovation© process

*vFTE (varaible Full Time Equivalent)

Bio-Modeling Systems: a leading Integrative Heuristic Systems Biology / Predictive Integrative Biology Mechanisms-Based Medicine company that delivers